Discussion 'Myeloma'
Next Generation Targeted Cancer Therapies – The Cellectar Story!
CureTalks launches its new series featuring biotech companies at the cutting edge of innovation and breakthrough research with the purpose of bringing their contributions to the fore and informing the patient community. This talk series will be hosted by Gary…
CLR 131 – A New Approach in Multiple Myeloma Treatment
CLR 131 is a targeted small-molecule that is being developed for the treatment of myeloma and lymphoma, as well as pediatric and head & neck cancers by Cellectar Biosciences. It works by delivering a radioactive, toxic compound directly to tumor…
ASH 2019 Annual Meeting Multiple Myeloma Updates
The 62nd ASH (American Society of Hematology) annual meeting was held in early December 2019. We are talking to Dr Shaji Kumar about new research presented at ASH, including disease-specific treatment updates on multiple myeloma, the role of precision medicine & clinical…
Multiple Myeloma Stem Cells and Drug Resistance in Myeloma Management
Multiple myeloma is a heterogenous plasma cell disorder that contains a small fraction of clonogenic stem cells, just like many other cancers. Although the exact nature and biological properties of these cells remain elusive, multiple myeloma stem cells (MMSCs) have…
Understanding the FDA approved New Drug, Selinexor and its Use in Multiple Myeloma
Recently, the FDA approved a new cancer drug called Selinexor. This drug has been found to be successful in treating multiple myeloma in patients who have exhausted all other existing treatment options. Selinexor works on a different mechanism compared to…